Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

PURPOSE: Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL, irrespective of high-risk features. Given the rel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lin, Thomas S., Ruppert, Amy S., Johnson, Amy J., Fischer, Beth, Heerema, Nyla A., Andritsos, Leslie A., Blum, Kristie A., Flynn, Joseph M., Jones, Jeffrey A., Hu, Weihong, Moran, Mollie E., Mitchell, Sarah M., Smith, Lisa L., Wagner, Amy J., Raymond, Chelsey A., Schaaf, Larry J., Phelps, Mitch A., Villalona-Calero, Miguel A., Grever, Michael R., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793044/
https://ncbi.nlm.nih.gov/pubmed/19826119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.6944
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados